Avestha Gengraine, Ranbaxy Pen Drug-Discovery Deal | GenomeWeb

NEW YORK, Sept. 6 (GenomeWeb News) - Avestha Gengraine Technologies, a bioinformatics company based in India, will help Ranbaxy Laboratories develop recombinant cell lines as part of a drug-discovery program, the companies said today.


Avestha Gengraine's research covers infectious diseases and degenerative and metabolic disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.